Accession Number:

ADA361700

Title:

Antibody-IL2 Fusion Protein Delivery by Gene Transfer

Descriptive Note:

Annual rept. 1 Oct 97-30 Sep 98

Corporate Author:

WISCONSIN UNIV-MADISON

Personal Author(s):

Report Date:

1998-10-01

Pagination or Media Count:

20.0

Abstract:

Our team has pursued preclinical and clinical investigations combining the administration of IL-2 with tumor reactive monoclonal antibodies. Preclinical models, developed by our collaborators R.Reisfeld and S.Gillies, have shown the antitumor efficacy of antibody-IL2 fusion proteins in murine models. The KS-IL2 fusion protein recognizes the KSA antigen expressed on a broad range of human carcinomas, including breast cancer and is effective at preventing outgrowth of the KSA positive, syngeneic CT26-KSA carcinoma cell line in mice. The experiments now underway in this research study are designed to help improve the future clinical efficacy of the KS-IL2 reagent by clarifying its actions, testing its efficacy in murine models simulating pitfalls with human immunotherapy, and translating these results to human application through in vitro studies.

Subject Categories:

  • Biochemistry
  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE